Family Medicine Doctors in Walnutport, PA Accepting Medicare
4 Family Medicine doctors found. Showing 1 - 4
 Thomas Edward Yablonski, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 215 N Best Ave, Walnutport, PA 18088 Phone: 610-760-7044 Fax: 610-760-8587 |
 Dr. Debra Ellen Cressman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 215 N Best Ave, Walnutport, PA 18088 Phone: 610-760-7044 Fax: 610-760-8587 |
Lisa Jill Doherty, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 330 N Best Ave, Walnutport, PA 18088 Phone: 610-760-8080 Fax: 610-760-8148 |
Colleen Manzella, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 330 N Best Ave, Walnutport, PA 18088 Phone: 610-760-8080 Fax: 610-760-8148 |
News Archive
ASBMB honors South Carolina researcher with Avanti Award for sphingolipid work
The American Society for Biochemistry and Molecular Biology has named Yusuf Hannun, professor and department chairman at the Medical University of South Carolina, in Charleston, S.C., the winner of the Avanti Award in Lipids.
Kefir may be great way for cancer survivors to enjoy post-exercise dairy drink, researchers say
Kefir may be a beneficial post-exercise beverage for cancer survivors. It means that cancer survivors can enjoy the nutritional support that milk provides without the potential for significant stomach upset, report researchers in the Journal of Dairy Science.
In-home occupational therapy reduces depression symptoms in patients with impaired vision
Johns Hopkins researchers report that in-home occupational therapy appears to reduce the rate and severity of depression in people at higher risk for the disorder because of seriously impaired vision.
FDA grants fast track designation to Synageva for SBC-102 program for Lysosomal Acid Lipase Deficiency
Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, announced today that their lead program, SBC-102, an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, currently in clinical trials, has been granted fast track designation by the U.S. Food and Drug Administration (FDA).
› Verified 3 days ago